Trust Company of Vermont’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $281K | Buy |
+3,104
| New | +$260K | 0.01% | 325 |
|
|
2025
Q4 | $251K | Buy |
2,945
+160
| +6% | +$13.1K | 0.01% | 322 |
|
|
2025
Q3 | $217K | Sell |
2,785
-100
| -3% | -$7.81K | 0.01% | 347 |
|
|
2025
Q2 | $226K | Sell |
2,885
-53
| -2% | -$3.95K | 0.01% | 334 |
|
|
2025
Q1 | $213K | Sell |
2,938
-190
| -6% | -$13.6K | 0.01% | 334 |
|
|
2024
Q4 | $232K | Buy |
3,128
+109
| +4% | +$7.63K | 0.01% | 326 |
|
|
2024
Q3 | $199K | Buy |
3,019
+801
| +36% | +$58.2K | 0.01% | 330 |
|
|
2024
Q2 | $205K | Buy |
2,218
+25
| +1% | +$2.21K | 0.01% | 314 |
|
|
2024
Q1 | $210K | Buy |
2,193
+914
| +71% | +$76.8K | 0.01% | 304 |
|
|
2023
Q4 | $97.5K | Buy |
1,279
+4
| +0.3% | +$278 | 0.01% | 353 |
|
|
2023
Q3 | $88.3K | Sell |
1,275
-72
| -5% | -$5.79K | 0.01% | 380 |
|
|
2023
Q2 | $127K | Hold |
1,347
| – | – | 0.01% | 362 |
|
|
2023
Q1 | $111K | Sell |
1,347
-112
| -8% | -$8.8K | 0.01% | 381 |
|
|
2022
Q4 | $109K | Buy |
1,459
+112
| +8% | +$8.63K | 0.01% | 372 |
|
|
2022
Q3 | $111K | Hold |
1,347
| – | – | 0.01% | 368 |
|
|
2022
Q2 | $128K | Buy |
+1,347
| New | +$139K | 0.01% | 353 |
|
|
2022
Q1 | – | Sell |
-1,319
| Closed | -$171K | – | 445 |
|
|
2021
Q4 | $171K | Buy |
+1,319
| New | +$154K | 0.01% | 334 |
|
|
2021
Q3 | – | Sell |
-1,319
| Closed | -$137K | – | 434 |
|
|
2021
Q2 | $137K | Buy |
1,319
+765
| +138% | +$72.1K | 0.01% | 356 |
|
|
2021
Q1 | $46K | Buy |
554
+29
| +6% | +$2.45K | ﹤0.01% | 470 |
|
|
2020
Q4 | $48K | Hold |
525
| – | – | ﹤0.01% | 453 |
|
|
2020
Q3 | $42K | Sell |
525
-150
| -22% | -$11.7K | ﹤0.01% | 449 |
|
|
2020
Q2 | $47K | Sell |
675
-84
| -11% | -$5.97K | ﹤0.01% | 445 |
|
|
2020
Q1 | $48K | Buy |
759
+300
| +65% | +$21.6K | ﹤0.01% | 442 |
|
|
2019
Q4 | $36K | Hold |
459
| – | – | ﹤0.01% | 517 |
|
|
2019
Q3 | $34K | Hold |
459
| – | – | ﹤0.01% | 532 |
|
|
2019
Q2 | $28K | Hold |
459
| – | – | ﹤0.01% | 564 |
|
|
2019
Q1 | $29K | Sell |
459
-117
| -20% | -$6.68K | ﹤0.01% | 550 |
|
|
2018
Q4 | $29K | Hold |
576
| – | – | ﹤0.01% | 547 |
|
|
2018
Q3 | $33K | Hold |
576
| – | – | ﹤0.01% | 578 |
|
|
2018
Q2 | $28K | Buy |
+576
| New | +$26.9K | ﹤0.01% | 628 |
|
|
2017
Q1 | – | Sell |
-45
| Closed | -$1K | – | 880 |
|
|
2016
Q4 | $1K | Buy |
+45
| New | +$1.46K | ﹤0.01% | 868 |
|
Other funds holding EW
Trust Company of Vermont's EW Position: Q2 2026 in Review
Trust Company of Vermont opened a new position in Edwards Lifesciences (EW) in Q2 2026: 3,104 shares worth $281K. The stake represents 0.01% of the portfolio and ranks #325 among its holdings. This is a return to the name: Trust Company of Vermont previously reported a position in EW as recently as Q4 2025.
Trust Company of Vermont first reported a position in EW in Q4 2016 and has held it in 31 quarters since. 1,338 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Trust Company of Vermont held 3,104 shares of Edwards Lifesciences worth $281K as of Q2 2026.
- Edwards Lifesciences was a new Trust Company of Vermont position in Q2 2026.
- Edwards Lifesciences made up 0.01% of Trust Company of Vermont's portfolio in Q2 2026, its #325 holding.
- Trust Company of Vermont first reported a position in Edwards Lifesciences in Q4 2016 and has held it in 31 quarters since.
- 1,338 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Trust Company of Vermont's 13F filing for Q2 2026, filed 7 Aug 2026.